Tianda Pharmaceuticals Ltd.

As of December 31, 2024, Tianda Pharmaceuticals Ltd. carries a market capitalization of 344.01M, placing it among publicly traded companies globally. Its enterprise value stands at 385.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2024, Tianda Pharmaceuticals Ltd. has 2.15B shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Tianda Pharmaceuticals Ltd. maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, Tianda Pharmaceuticals Ltd.'s stock has declined approximately 33.33% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.13.

As of December 31, 2024, Tianda Pharmaceuticals Ltd. holds 85.69M in cash and equivalents against 127.45M in total debt, resulting in a net debt position of 36.39M. Total book value stands at 505.84M, with working capital of -35.12M providing operational flexibility.

Tianda Pharmaceuticals Ltd.'s most recent stock split took place on July 8, 2010 with a 38:55 split ratio.